Ashish Sarraju1, Gabriela Spencer-Bonilla2, Sukyung Chung2, Sofia Gomez2, Jiang Li3, Paul Heidenreich4, Latha Palaniappan5, Fatima Rodriguez6. 1. Division of Cardiovascular Medicine and Cardiovascular Institute, Department of Medicine, Stanford University School of Medicine, 870 Quarry Road, Falk CVRC, Stanford, CA, 94305-5406, USA. asarraju@stanford.edu. 2. Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. 3. Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA. 4. Division of Cardiology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. 5. Division of Primary Care and Population Health, Stanford University School of Medicine, Stanford, CA, USA. 6. Division of Cardiovascular Medicine and Cardiovascular Institute, Department of Medicine, Stanford University School of Medicine, 870 Quarry Road, Falk CVRC, Stanford, CA, 94305-5406, USA.
Abstract
BACKGROUND: There remains uncertainty regarding optimal primary atherosclerotic cardiovascular disease (ASCVD) prevention practices for older adults. OBJECTIVE: To assess statin treatment patterns and incident ASCVD among older patients for primary prevention across the spectrum of ASCVD risk. DESIGN: Retrospective cohort study of participants without ASCVD aged 65-79 years. Patients were stratified by age (65-69, 70-75, > 75 years) and 10-year ASCVD risk category (low/borderline, intermediate, high) based on the Pooled Cohort Equations. Multivariable logistic regressions were used to identify predictors of moderate- or high-intensity statin prescriptions. Cox proportional models were used to estimate hazard ratios (HRs) for incident ASCVD. PARTICIPANTS: Patients aged 65-79 years without ASCVD from a Northern California health system. MAIN MEASURES: Statin prescriptions and incident ASCVD events. KEY RESULTS: There were 54,066 patients, with 10,288 (19%) aged > 75 years and 57% women. Compared with younger groups, adults > 75 years were less likely to be prescribed moderate- or high-intensity statin prescriptions across ASCVD risk groups (all p < 0.001); this persisted after multivariable adjustment including for ASCVD risk (odds ratio [OR] 0.80, 95% confidence interval [CI] 0.74-0.86). Adults > 75 years were more likely to experience incident ASCVD (HR 1.42, 95% CI 1.23-1.63). Women (OR 0.85, 95% CI 0.81-0.89) and underweight older adults (OR 0.45, 95% CI 0.33-0.61) were also less likely to receive moderate- or high-intensity statins. CONCLUSIONS: Among older adults aged 65-79 years without prior ASCVD, those > 75 years of age were less likely to receive moderate- or high-intensity statins regardless of ASCVD risk compared with their younger counterparts, while experiencing more incident ASCVD. Efforts are warranted to study the reasons for age-based differences in statin use in older adults, particularly those at highest ASCVD risk.
BACKGROUND: There remains uncertainty regarding optimal primary atherosclerotic cardiovascular disease (ASCVD) prevention practices for older adults. OBJECTIVE: To assess statin treatment patterns and incident ASCVD among older patients for primary prevention across the spectrum of ASCVD risk. DESIGN: Retrospective cohort study of participants without ASCVD aged 65-79 years. Patients were stratified by age (65-69, 70-75, > 75 years) and 10-year ASCVD risk category (low/borderline, intermediate, high) based on the Pooled Cohort Equations. Multivariable logistic regressions were used to identify predictors of moderate- or high-intensity statin prescriptions. Cox proportional models were used to estimate hazard ratios (HRs) for incident ASCVD. PARTICIPANTS: Patients aged 65-79 years without ASCVD from a Northern California health system. MAIN MEASURES: Statin prescriptions and incident ASCVD events. KEY RESULTS: There were 54,066 patients, with 10,288 (19%) aged > 75 years and 57% women. Compared with younger groups, adults > 75 years were less likely to be prescribed moderate- or high-intensity statin prescriptions across ASCVD risk groups (all p < 0.001); this persisted after multivariable adjustment including for ASCVD risk (odds ratio [OR] 0.80, 95% confidence interval [CI] 0.74-0.86). Adults > 75 years were more likely to experience incident ASCVD (HR 1.42, 95% CI 1.23-1.63). Women (OR 0.85, 95% CI 0.81-0.89) and underweight older adults (OR 0.45, 95% CI 0.33-0.61) were also less likely to receive moderate- or high-intensity statins. CONCLUSIONS: Among older adults aged 65-79 years without prior ASCVD, those > 75 years of age were less likely to receive moderate- or high-intensity statins regardless of ASCVD risk compared with their younger counterparts, while experiencing more incident ASCVD. Efforts are warranted to study the reasons for age-based differences in statin use in older adults, particularly those at highest ASCVD risk.
Authors: Quyen Ngo-Metzger; Samuel Zuvekas; Paul Shafer; Howard Tracer; Amanda E Borsky; Arlene S Bierman Journal: J Am Board Fam Med Date: 2019 Nov-Dec Impact factor: 2.657
Authors: Hasan Rehman; Sarah T Ahmed; Julia Akeroyd; Dhruv Mahtta; Xiaoming Jia; Mahmoud Al Rifai; Khurram Nasir; Hani Jneid; Mirza U Khalid; Mahboob Alam; Peter P Toth; Salim S Virani Journal: Am J Cardiol Date: 2019-07-25 Impact factor: 2.778
Authors: Andrew Ward; Ashish Sarraju; Sukyung Chung; Jiang Li; Robert Harrington; Paul Heidenreich; Latha Palaniappan; David Scheinker; Fatima Rodriguez Journal: NPJ Digit Med Date: 2020-09-23
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Baris Gencer; Nicholas A Marston; KyungAh Im; Christopher P Cannon; Peter Sever; Anthony Keech; Eugene Braunwald; Robert P Giugliano; Marc S Sabatine Journal: Lancet Date: 2020-11-10 Impact factor: 202.731
Authors: Michael G Nanna; Ann Marie Navar; Tracy Y Wang; Xiaojuan Mi; Salim S Virani; Michael J Louie; L Veronica Lee; Anne C Goldberg; Veronique L Roger; Jennifer Robinson; Eric D Peterson Journal: J Am Heart Assoc Date: 2018-05-08 Impact factor: 5.501
Authors: Milly A van der Ploeg; Carmen Floriani; Wilco P Achterberg; Jonathan M K Bogaerts; Jacobijn Gussekloo; Simon P Mooijaart; Sven Streit; Rosalinde K E Poortvliet; Yvonne M Drewes Journal: J Am Geriatr Soc Date: 2019-10-30 Impact factor: 5.562